Cannabinoid-Infused Powder for Lymphatic Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cannabinoids like CBD, CBG, and CBN have low oral bioavailability and are subject to extensive first-pass metabolism in the liver, leading to inconsistent absorption and reduced effectiveness in treating medical conditions.
Innovation Solution
Administering a cannabinoid-infused powder comprising cannabinoids, an edible carrier, and an edible oil with long chain triglycerides, which facilitates absorption via the lymphatic system, reducing liver metabolism and enhancing delivery to the central nervous system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cannabinoids are administered orally, then they can be delivered systemically, but their bioavailability is low and absorption is inconsistent due to first-pass metabolism in the liver
Solution Approach 1:
The patent uses long-chain triglycerides as an intermediary substance to facilitate lymphatic absorption of cannabinoids. The triglycerides form micelles that solubilize the lipophilic cannabinoids and transport them through the lymphatic system, bypassing hepatic first-pass metabolism and improving bioavailability
Solution Approach 2:
The patent changes the physical-chemical parameters of the cannabinoid formulation by incorporating specific ratios of long-chain to medium-chain triglycerides (at least 2:1, preferably at least 4:1). This parameter change alters the absorption pathway from portal circulation to lymphatic circulation, thereby reducing first-pass metabolism and enhancing reliability of cannabinoid delivery
2Reliability
If cannabinoids are administered to achieve effective therapeutic levels, then treatment efficacy improves, but the amount of cannabinoid required increases due to poor bioavailability
Solution Approach 1:
The long-chain triglycerides act as a delivery mediator that efficiently transports cannabinoids through the lymphatic system to systemic circulation. This intermediary mechanism significantly improves the fraction of administered cannabinoid that reaches therapeutic sites, reducing the total quantity needed for effective treatment
Solution Approach 2:
The patent creates a composite formulation combining cannabinoids with specific triglyceride ratios (long-chain to medium-chain at least 2:1). This composite material leverages the solubilizing and transport properties of triglycerides to enhance cannabinoid bioavailability, allowing lower doses to achieve therapeutic efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances bioavailability, reduces first-pass metabolism, and improves distribution to the central nervous system, allowing for effective treatment of conditions such as pain, anxiety, and insomnia, while potentially lowering opioid doses for pain relief.
Implementation Method 1
cannabinoid-infused powders comprising a cannabinoid (e.g., CBD, CBG, CBN, or mixtures thereof), an edible carrier, and an edible oil comprising long chain triglycerides... are absorbed largely via the lymphatic system
Implementation Method 2
reduced first-pass effect and metabolism in the liver
Data Source
AI summary
The disclosure provides compositions and methods of treatment by enhanced delivery of cannabinoids using cannabinoid-infused powders comprising a cannabinoid API, an edible carrier, and an edible oil comprising long chain triglycerides.